Anzeige
Mehr »
Donnerstag, 23.04.2026 - Börsentäglich über 12.000 News
Diese Aktie zündet die nächste Explorationsstufe - und der Markt beginnt aufzuwachen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 920657 | ISIN: FR0000120578 | Ticker-Symbol: SNW
Tradegate
22.04.26 | 21:39
80,80 Euro
+0,21 % +0,17
1-Jahres-Chart
SANOFI SA Chart 1 Jahr
5-Tage-Chart
SANOFI SA 5-Tage-Chart
RealtimeGeldBriefZeit
80,3680,9222.04.
80,3780,8922.04.

Aktuelle News zur SANOFI Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiSanofi: Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria258Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria Approval for children aged two to 11 years with...
► Artikel lesen
SANOFI Aktie jetzt für 0€ handeln
MiSanofi Q1 2026 Earnings Preview28
MiFDA delays decision on Sanofi's subcutaneous Sarclisa13
MiSanofi Eyes First On-Body Injector Cancer Therapy As FDA Delays Decision14
MiEntschlüsselung fehlregulierter Immunreaktionen: Forschung bei Sanofi an neuen Therapieoptionen für Autoimmunerkrankungen354Frankfurt/Main (ots) - Autoimmunerkrankungen betreffen weltweit Millionen von Patient*innen. Sie erfordern oft lebenslange Behandlung. Trotz bedeutender medizinischer Fortschritte sprechen nicht alle...
► Artikel lesen
MiSanofi Says FDA Extends Review Of Sarclisa SC By Up To Three Months442PARIS (dpa-AFX) - Sanofi SA (SNY) on Wednesday said the U.S. Food and Drug Administration has extended by up to three months the timeline to review Sarclisa subcutaneous (SC) formulation in...
► Artikel lesen
MiSanofi Wins FDA Nod To Expand Use Of Type 1 Diabetes Drug In Younger Children302PARIS (dpa-AFX) - Sanofi SA (SNY) on Wednesday said the U.S. Food and Drug Administration has approved Tzield to expand its indication from patients aged eight years and older to those as young...
► Artikel lesen
MiFDA expands Sanofi's Tzield use to children as young as 1 for type 1 diabetes delay6
MiFDA erweitert Zulassung für Sanofis Diabetes-Medikament Tzield auf Kleinkinder15
MiFDA approves Sanofi's Tzield for children as young as one year5
MiSanofi: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US273Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US Paris, April 22, 2026. The US Food and Drug Administration (FDA) has extended by up to three months the target...
► Artikel lesen
MiSanofi: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children260Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children Expanded approval includes children aged one year and above with stage 2 T1D to delay the onset...
► Artikel lesen
MoSanofi touts tolerability of COVID shot Nuvaxovid in head-to-head trial vs. Moderna's mNexspike11
SoSanofi's Nuvaxovid Shows Superior Tolerability Over Moderna's MNEXSPIKE In COMPARE Study742PARIS (dpa-AFX) - Sanofi's (SNY, SNYNF,SAN.PA) protein-based COVID-19 vaccine, Nuvaxovid (NVX-CoV2705), demonstrated a significantly better tolerability profile compared to Moderna's latest...
► Artikel lesen
SaSanofi: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study837ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study First head-to-head, double-blind, randomized phase 4 study powered to directly compare the...
► Artikel lesen
16.04.DKSH erhält Aufträge von Yeastup und Sanofi18
15.04.Sanofi - 6-K, Report of foreign issuer13
14.04.Sanofi: Information concerning the total number of voting rights and shares - March 20263
13.04.Regeneron und Sanofi bekommen Dupixent-Zulassung für Kinder mit CSU555DJ Regeneron und Sanofi bekommen Dupixent-Zulassung für Kinder mit CSU Von Colin Kellaher DOW JONES--Regeneron Pharmaceuticals und Sanofi haben für ihren Blockbuster-Entzündungshemmer Dupixent...
► Artikel lesen
13.04.Regeneron, Sanofi Secure EU Nod To Expand Dupixent Use In Young Children With CSU358PARIS (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi SA (SNY) on Monday said the European Commission has approved Dupixent for treating moderate-to-severe chronic spontaneous...
► Artikel lesen
Weiter >>
777 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
3,1,48